Trial Profile

A phase 2b/3 study of iCM 012 for the treatment of injuries in kidney transplants

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TUM 012 (Primary)
Indications Reperfusion injury
Focus Registrational; Therapeutic Use

Most Recent Events

14 Dec 2023 New trial record
15 Nov 2023 According to a Icoat medical media release, extensive preparations were made for this pivotal clinical study, including visits to hospitals around the US and Europe. Nearly 40 transplant centers were included in the evaluation with positive response. The company's goal is to have the study approved in H1 2024 and then start enrolling patients

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com